26. HTLV-1関連脊髄症 HTLV-1-associated myelopathy Clinical trials / Disease details
臨床試験数 : 28 / 薬物数 : 48 - (DrugBank : 28) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 127
Showing 1 to 10 of 28 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05240612 (ClinicalTrials.gov) | March 2022 | 13/2/2022 | A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) | A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM) A Clinical Pharmacological Study of MT-3921 in Subjects With Human T-cell Leukemia Virus Type 1 (HTL ... | HTLV-1-Associated Myelopathy (HAM) | Biological: MT-3921;Biological: Placebo | Mitsubishi Tanabe Pharma Corporation | NULL | Not yet recruiting | 20 Years | N/A | All | 15 | Phase 1 | NULL |
2 | NCT04799288 (ClinicalTrials.gov) | September 24, 2021 | 13/3/2021 | Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis | Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis | HAM/TSP | Drug: Teriflunomide | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1/Phase 2 | United States |
3 | NCT04301076 (ClinicalTrials.gov) | June 15, 2020 | 6/3/2020 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (EPOCH) for Adult T-Cell Leukemia-Lymphoma (ATL) Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Tre ... | A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-C ... | Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Ly ... | Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Prednisone;Drug: Vincristine Sulfate Drug: Cyclophosphamide;Drug: DoxorubicinHydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Predn ... | National Cancer Institute (NCI) | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 1 | United States |
4 | NCT02655471 (ClinicalTrials.gov) | July 1, 2017 | 16/11/2015 | Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis- Human T-Lymphotropic Viru ... | Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic ParaparesisAssociated With Infect ... | HTLV-I Infections;Tropical Spastic Paraparesis | Drug: Raltegravir and Zidovudine | Universidad Peruana Cayetano Heredia | Merck Sharp & Dohme Corp. | Completed | 18 Years | N/A | All | 10 | Early Phase 1 | Peru |
5 | JPRN-JMA-IIA00324 | 29/06/2017 | 23/01/2018 | A Phase 3 Study of KW-0761 (Mogamulizumab) in Subjects with HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0 ... | HTLV-1 associated Myelopathy (HAM) | Intervention type:DRUG. Intervention1:KW-0761, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP. Control intervention1:Placebo, Dose form:INJECTION, Route of administration:INTRAVENOUS DRIP. Intervention type:DRUG. Intervention1:KW-0761, Dose form:INJECTION, Route of administration:INTRAVEN ... | Kyowa Kirin Co., Ltd | NULL | Completed | >=20 YEARS | No Limit | BOTH | 52 | Phase 3 | Japan |
6 | JPRN-JapicCTI-173608 | 01/6/2017 | 06/06/2017 | A Phase 3 Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Subjects with HTLV-1 Associated Myelopathy (HAM) A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0 ... | HTLV-1 associated Myelopathy (HAM) | Intervention name : KW-0761 INN of the intervention : Mogamulizumab Dosage And administration of the intervention : 0.3 mg/kg, IV Intervention name : KW-0761 INN of the intervention : Mogamulizumab Dosage And administration of the i ... | Kyowa Hakko Kirin Co., Ltd. | NULL | complete | 20 | BOTH | 52 | Phase 3 | NULL | |
7 | NCT03191526 (ClinicalTrials.gov) | May 22, 2017 | 13/6/2017 | A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0 ... | HTLV-1 Associated Myelopathy | Drug: KW-0761 0.3 mg/kg IV;Drug: Placebo (saline) | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 66 | Phase 3 | Japan |
8 | NCT03075553 (ClinicalTrials.gov) | May 17, 2017 | 1/3/2017 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral ... | Blastic Plasmacytoid Dendritic Cell Neoplasm;Hepatosplenic T-Cell Lymphoma;HTLV-1 Infection;NK-Cell Lymphoma, Unclassifiable;Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative;Recurrent Adult T-Cell Leukemia/Lymphoma;Recurrent Anaplastic Large Cell Lymphoma;Recurrent Angioimmunoblastic T-cell Lymphoma;Recurrent Enteropathy-Associated T-Cell Lymphoma;Recurrent Mycosis Fungoides;Refractory Adult T-Cell Leukemia/Lymphoma;Refractory Anaplastic Large Cell Lymphoma;Refractory Angioimmunoblastic T-cell Lymphoma;Refractory Enteropathy-Associated T-Cell Lymphoma;Refractory Mycosis Fungoides;Refractory Nasal Type Extranodal NK/T-Cell Lymphoma;Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified Blastic Plasmacytoid Dendritic Cell Neoplasm;Hepatosplenic T-Cell Lymphoma;HTLV-1Infection;NK-Cell L ... | Other: Laboratory Biomarker Analysis;Biological: Nivolumab | Mayo Clinic | National Cancer Institute (NCI) | Terminated | 18 Years | N/A | All | 12 | Phase 2 | United States |
9 | NCT02631746 (ClinicalTrials.gov) | February 21, 2017 | 15/12/2015 | Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma | Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection;Lymphomatous Adult T-Cell Leukemia/Lymphoma;Smoldering Adult T-Cell Leukemia/Lymphoma Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Ly ... | Other: Laboratory Biomarker Analysis;Biological: Nivolumab;Other: Pharmacogenomic Study | National Cancer Institute (NCI) | NULL | Completed | 18 Years | N/A | All | 3 | Phase 2 | United States |
10 | JPRN-UMIN000024086 | 2016/09/16 | 20/09/2016 | Phase IIb clinical trial of steroid therapy in patients with HAM(Non progressor) | HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP) | Drugs which possibly affect assessment in the study (e.g. methylprednisolone, prednisolone and other agents targeted to HAM) will be forbidden or limited until Week 48 and periodic evaluation and tests will be performed. Drugs which possibly affect assessment in the study (e.g. methylprednisolone, prednisoloneand other ... | St. Marianna University School of Medicine Hospital | NULL | Recruiting | 18years-old | Not applicable | Male and Female | 5 | Phase 2 | Japan |